Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
R&D head reflects on the accelerated approval program in the wake of FDA's February meeting with ODAC.
You may also be interested in...
Pfizer's Crizotinib Eases Past FDA With Targeted Population
Xalkori is the second targeted oncologic approved with a companion diagnostic this year, FDA says, following Roche's Zelboraf just 10 days prior.
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.
Adcetris Review Adds Some Clarity To Principles For Accelerated Approval
Sponsors seeking insight into when a single-arm trial will be deemed acceptable support for accelerated approval by FDA and its Oncologic Drugs Advisory Committee can look to the recent review of Seattle Genetics’ Adcetris (brentuximab) for clues.